{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:57:32Z","timestamp":1770019052180,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770570"],"award-info":[{"award-number":["81770570"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801990"],"award-info":[{"award-number":["81801990"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012457","name":"Chongqing Basic and Frontier Research Project","doi-asserted-by":"publisher","award":["cstc2019jcyj-msxmX0007"],"award-info":[{"award-number":["cstc2019jcyj-msxmX0007"]}],"id":[{"id":"10.13039\/501100012457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12072-020-10024-2","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T06:14:54Z","timestamp":1583302494000},"page":"338-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"Fang","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuxue","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiwen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2878-9149","authenticated-orcid":false,"given":"Wenwei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"issue":"4","key":"10024_CR1","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","volume":"59","author":"EM Sokal","year":"2013","unstructured":"Sokal EM, Paganelli M, Wirth S, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol 2013;59(4):814\u2013829","journal-title":"J Hepatol"},{"key":"10024_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/1743-422X-10-239","volume":"10","author":"WH Gerlich","year":"2013","unstructured":"Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J 2013;10:239","journal-title":"Virol J"},{"issue":"15","key":"10024_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1056\/NEJM197504102921503","volume":"292","author":"CE Stevens","year":"1975","unstructured":"Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292(15):771\u2013774","journal-title":"N Engl J Med"},{"issue":"5","key":"10024_CR4","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1053\/j.gastro.2007.08.010","volume":"133","author":"SE Livingston","year":"2007","unstructured":"Livingston SE, Simonetti JP, Bulkow LR, et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007;133(5):1452\u20131457","journal-title":"Gastroenterology"},{"issue":"26","key":"10024_CR5","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","volume":"336","author":"MH Chang","year":"1997","unstructured":"Chang MH, Chen CJ, Lai MS, Taiwan Childhood Hepatoma Study Group, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336(26):1855\u20131859","journal-title":"N Engl J Med"},{"key":"10024_CR6","doi-asserted-by":"crossref","unstructured":"Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev 2006;(2):Cd004790","DOI":"10.1002\/14651858.CD004790.pub2"},{"issue":"4","key":"10024_CR7","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1053\/j.gastro.2007.02.055","volume":"132","author":"YH Ni","year":"2007","unstructured":"Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007;132(4):1287\u20131293","journal-title":"Gastroenterology"},{"issue":"6","key":"10024_CR8","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1093\/infdis\/170.6.1418","volume":"170","author":"RD Burk","year":"1994","unstructured":"Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994;170(6):1418\u20131423","journal-title":"J Infect Dis"},{"issue":"1","key":"10024_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jhep.2013.02.015","volume":"59","author":"WH Wen","year":"2013","unstructured":"Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013;59(1):24\u201330","journal-title":"J Hepatol"},{"issue":"2","key":"10024_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/hep.27034","volume":"60","author":"H Zhang","year":"2014","unstructured":"Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology (Baltimore, MD) 2014;60(2):468\u2013476","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"5","key":"10024_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.cgh.2012.01.019","volume":"10","author":"CQ Pan","year":"2012","unstructured":"Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10(5):520\u2013526","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10024_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/liv.12959","volume":"36","author":"B Njei","year":"2016","unstructured":"Njei B, Gupta N, Ewelukwa O, Ditah I, Foma M, Lim JK. Comparative efficacy of antiviral therapy in preventing vertical transmission of hepatitis B: a network meta-analysis. Liver Int 2016;36(5):634\u2013641","journal-title":"Liver Int"},{"issue":"2","key":"10024_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64(2):163\u2013171","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10024_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijgo.2011.03.004","volume":"114","author":"M Yu","year":"2011","unstructured":"Yu M, Ji Y, Jiang H, Ju L, Wu K, Kan N. Efficacy of peripartum antiviral treatment for hepatic failure due to hepatitis B virus. Int J Gynaecol Obstet 2011;114(1):33\u201336","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"10024_CR15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2014.04.038","volume":"61","author":"AJ Greenup","year":"2014","unstructured":"Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014;61(3):502\u2013507","journal-title":"J Hepatol"},{"issue":"3","key":"10024_CR16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/jvh.13036","volume":"26","author":"J Song","year":"2019","unstructured":"Song J, Yang F, Wang S, et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis. J Viral Hepat 2019;26(3):397\u2013406","journal-title":"J Viral Hepat"},{"issue":"1","key":"10024_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/hep.28302","volume":"63","author":"RS Brown Jr","year":"2016","unstructured":"Brown RS Jr, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology (Baltimore, MD) 2016;63(1):319\u2013333","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"10024_CR18","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore, MD) 2018;67(4):1560\u20131599","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"2","key":"10024_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL","year":"2017","unstructured":"EASL. EASL Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67(2):370\u2013398","journal-title":"J Hepatol"},{"key":"10024_CR20","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s10620-012-2187-3","volume":"57","author":"CQ Pan","year":"2012","unstructured":"Pan CQ, Mi LJ, Bunchorntavakul C, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012;57:2423\u20132429","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10024_CR21","first-page":"503","volume":"24","author":"X Cao","year":"2019","unstructured":"Cao X, Guan Y, Li Q, Zhou X, Gaowei L. Comparison of the effects of tenofovir and telbivudine combined with dual immunization regimen on blocking mother-to-child transmission of HBV during pregnancy. Chin Hepatol 2019;24(5):503\u2013506 (in Chinese)","journal-title":"Chin Hepatol"},{"key":"10024_CR22","first-page":"73","volume":"22","author":"W Chen","year":"2017","unstructured":"Chen W, Song S, He H, Qian L. Comparison of efficacy and safety of tenofovir and telbivudine in preventing HBV mother-to-child transmission during pregnancy. Shandong Med J 2017;22:73\u201375 (in Chinese)","journal-title":"Shandong Med J"},{"issue":"11","key":"10024_CR23","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/jvh.12212","volume":"21","author":"A Ayres","year":"2014","unstructured":"Ayres A, Yuen L, Jackson KM, et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J Viral Hepat 2014;21(11):809\u2013817","journal-title":"J Viral Hepat"},{"issue":"Suppl 1","key":"10024_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jvh.12066","volume":"20","author":"M Liu","year":"2013","unstructured":"Liu M, Cai H, Yi W. Safety of telbivudine treatment for chronic hepatitis B for the entire pregnancy. J Viral Hepat 2013;20(Suppl 1):65\u201370","journal-title":"J Viral Hepat"},{"issue":"1","key":"10024_CR25","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","volume":"140","author":"EJ Heathcote","year":"2011","unstructured":"Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011;140(1):132\u2013143","journal-title":"Gastroenterology"},{"issue":"5","key":"10024_CR26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jhep.2012.06.031","volume":"57","author":"RS Brown Jr","year":"2012","unstructured":"Brown RS Jr, Verna EC, Pereira MR, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol 2012;57(5):953\u2013959","journal-title":"J Hepatol"},{"issue":"6","key":"10024_CR27","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00404-011-2064-x","volume":"284","author":"J Kakogawa","year":"2011","unstructured":"Kakogawa J, Sakurabashi A, Sadatsuki M, Gomibuchi H, Minoura S. Chronic hepatitis B infection in pregnancy illustrated by a case of successful treatment with entecavir. Arch Gynecol Obstet 2011;284(6):1595\u20131596","journal-title":"Arch Gynecol Obstet"},{"key":"10024_CR28","first-page":"91","volume":"21","author":"G Yanqiu","year":"2018","unstructured":"Yanqiu G. Efficacy and safety of entecavir in pregnant women with viral hepatitis. Women\u2019s Health Res 2018;21:91\u201392 (in Chinese)","journal-title":"Women\u2019s Health Res"},{"issue":"5","key":"10024_CR29","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/jac\/dkt532","volume":"69","author":"M Markowitz","year":"2014","unstructured":"Markowitz M, Zolopa A, Squires K, et al. Phase I\/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother 2014;69(5):1362\u20131369","journal-title":"J Antimicrob Chemother"},{"key":"10024_CR30","first-page":"67","volume":"21","author":"JD Momper","year":"2018","unstructured":"Momper JD, Best B, Wang J, et al. Tenofovir alafenamide pharmacokinetics with and without cobicistat in pregnancy. J Int AIDS Soc 2018;21:67","journal-title":"J Int AIDS Soc"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-020-10024-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10024-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:04:42Z","timestamp":1695866682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-020-10024-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10024"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10024-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"7 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Fang Jia, Fuxue Deng, Shiwen Tong, Shiying Li, Hong Ren and Wenwei Yin declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}